Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...
A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...
Please provide your email address to receive an email when new articles are posted on . Patients with HER2-positive metastatic breast cancer had a real-world PFS of 1 year on trastuzumab deruxtecan.
Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients ...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy ...
MedPage Today on MSN
For Your Patients: A Look at Promising New Treatments for Gastric Cancer
Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...
The EMA validation of T-DXd with pertuzumab could change the standard of care for HER2-positive metastatic breast cancer in ...
Cardiotoxicity is an important adverse effect of trastuzumab in the treatment of breast cancer. Particularly in the adjuvant setting, a high risk of cardiotoxicity is unacceptable, since the ...
Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results